Guangzhou Intl Bio Island attracts 2 more major projects

Two major projects invested in by Jiangsu Hengrui Medicine and AstraZeneca will settle in Guangzhou International Bio Island.

The southern headquarters and R&D center of Jiangsu Hengrui Medicine, a Fortune China 500 company and China's largest supplier of antitumor drugs, surgical drugs, as well as contrast agents, came under construction recently.

With a floor area of 45,000 square meters, the headquarters will become a world leading biomedical R&D center, clinical experiment center, and clinical data center. It will advance research on antibody conjugates, bi-specific antibodies, antibody fragments, and tumor immunotherapy, while developing new drugs for tumors, diabetes, autoimmune diseases, as well as cardiovascular diseases.

An artist rendering of Jiangsu Hengrui Medicine's southern headquarters.

AstraZeneca, a world-renowned pharmaceutical enterprise specializing in the R&D, production, and sales of drugs for respiratory, tumor, cardiovascular, as well as kidney diseases, will set up its southern China headquarters on the island.

Once operational in 2021, the facility will focus on drug sales, R&D, marketing, and incubation. It will include the Guangzhou Biological Diagnosis Center, which will make innovations in diagnosis technology, elevate genetic testing capability, and improve the molecular pathology detection ability of county hospitals through trainings.

Share - WeChat